Gempharmatech Co. Ltd. A (SHG:688046) — Stock Price
Gempharmatech Co. Ltd. A (SHG:688046) is currently trading at CN¥35.06 CNY, down 2.39% today. Over the past 52 weeks, shares have ranged between CN¥13.04 and CN¥40.95. This page tracks Gempharmatech Co. Ltd. A's live share price on the SHG exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Gempharmatech Co. Ltd. A (688046) market capitalisation.
Gempharmatech Co. Ltd. A (688046) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Gempharmatech Co. Ltd. A's daily closing share price and trading volume on the SHG exchange over the past year, giving a clear view of recent price momentum and liquidity.
Gempharmatech Co. Ltd. A Income Statement — Revenue, Profit & Earnings by Year
Gempharmatech Co. Ltd. A's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Revenue | CN¥686.84 Million | CN¥622.19 Million | CN¥516.55 Million | CN¥393.79 Million | CN¥261.92 Million |
| Cost of Revenue | CN¥261.05 Million | CN¥201.52 Million | CN¥147.82 Million | CN¥101.09 Million | CN¥73.24 Million |
| Gross Profit | CN¥425.78 Million | CN¥420.67 Million | CN¥368.73 Million | CN¥292.70 Million | CN¥188.68 Million |
| Research & Development | CN¥87.13 Million | CN¥96.60 Million | CN¥82.93 Million | CN¥55.20 Million | CN¥48.22 Million |
| SG&A | CN¥110.52 Million | CN¥84.91 Million | CN¥73.26 Million | CN¥58.80 Million | CN¥35.64 Million |
| Total Operating Expenses | CN¥564.49 Million | CN¥455.84 Million | CN¥344.93 Million | CN¥243.20 Million | CN¥164.24 Million |
| Operating Income | CN¥122.35 Million | CN¥166.35 Million | CN¥171.62 Million | CN¥150.59 Million | CN¥97.67 Million |
| EBITDA | — | — | CN¥213.25 Million | CN¥172.87 Million | CN¥108.91 Million |
| EBIT | — | — | — | — | — |
| Interest Expense | CN¥4.30 Million | CN¥2.76 Million | CN¥495.53K | CN¥744.85K | CN¥723.98K |
| Income Before Tax | CN¥119.21 Million | CN¥161.29 Million | CN¥173.68 Million | CN¥143.31 Million | CN¥91.35 Million |
| Income Tax Expense | — | — | — | — | — |
| Net Income | CN¥109.82 Million | CN¥158.91 Million | CN¥164.67 Million | CN¥124.93 Million | CN¥76.43 Million |
Gempharmatech Co. Ltd. A Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Gempharmatech Co. Ltd. A's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Assets | CN¥2.57 Billion | CN¥2.58 Billion | CN¥2.25 Billion | CN¥1.05 Billion | CN¥883.19 Million |
| Total Current Assets | CN¥1.71 Billion | CN¥1.66 Billion | CN¥1.47 Billion | CN¥706.93 Million | CN¥647.25 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | CN¥467.34 Million | CN¥637.72 Million | CN¥791.24 Million | CN¥205.80 Million | — |
| Net Receivables | CN¥350.81 Million | CN¥269.39 Million | CN¥185.22 Million | CN¥118.57 Million | CN¥90.68 Million |
| Inventory | CN¥54.20 Million | CN¥47.09 Million | CN¥49.47 Million | CN¥30.08 Million | CN¥17.32 Million |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | — | — | — | — | — |
| Total Liabilities | CN¥437.92 Million | CN¥452.93 Million | CN¥276.00 Million | CN¥268.78 Million | CN¥225.95 Million |
| Total Current Liabilities | CN¥371.20 Million | CN¥366.41 Million | CN¥214.07 Million | CN¥191.74 Million | CN¥149.47 Million |
| Long-term Debt | — | — | — | CN¥20.03 Million | — |
| Net Debt | — | — | — | — | — |
| Total Stockholder Equity | CN¥2.13 Billion | CN¥2.12 Billion | CN¥1.98 Billion | CN¥785.63 Million | CN¥657.24 Million |
| Retained Earnings | CN¥435.31 Million | CN¥411.85 Million | CN¥280.99 Million | CN¥129.84 Million | CN¥19.20 Million |
Gempharmatech Co. Ltd. A Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Gempharmatech Co. Ltd. A generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | CN¥90.31 Million | CN¥116.57 Million | CN¥105.98 Million | CN¥113.31 Million | CN¥129.79 Million |
| Capital Expenditures | CN¥113.68 Million | CN¥205.90 Million | CN¥190.31 Million | CN¥89.07 Million | CN¥167.07 Million |
| Free Cash Flow | CN¥-23.36 Million | CN¥-89.33 Million | CN¥-84.33 Million | CN¥24.24 Million | CN¥-37.28 Million |
| Investing Cash Flow | — | — | — | — | — |
| Financing Cash Flow | — | — | — | — | — |
| Dividends Paid | CN¥80.11 Million | CN¥17.87 Million | CN¥283.50K | CN¥679.96K | CN¥672.32K |
| Stock-Based Compensation | — | — | — | — | — |
| Depreciation | CN¥84.85 Million | CN¥53.73 Million | CN¥39.07 Million | CN¥28.81 Million | CN¥16.83 Million |
| Change in Cash | CN¥141.22 Million | CN¥138.40 Million | CN¥128.08 Million | CN¥-230.65 Million | CN¥302.27 Million |
Gempharmatech Co. Ltd. A Earnings History — EPS Actual vs. Analyst Estimates
Track Gempharmatech Co. Ltd. A's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Apr 19, 2023 | 0.09 | — | — |
| Oct 30, 2022 | 0.11 | — | — |
| Aug 19, 2022 | 0.13 | — | — |